Looking back on 2020 and looking forward to 2021, we invite the most representative industry leaders in the bio-industry, Let's listen to their new year's dearest voice!

This Spring Festival Special invites Dr. Zhu Xiangyang, the general manager of Huabo Biopharm (Shanghai) Co., Ltd. and Shanghai Huaota Biopharmaceutical Co., Ltd., as our guest to talk about his dearest voice in the New Year.

Question: Please use one sentence or one word to summarize your 2020 and explain the reasons.

Answer: ‘Grateful

In 2020, we experienced the Covid-19 pandemic crisis that has not been seen in a century. Countries, companies, and individuals have all endured difficult challenges, and we all work together to overcome the difficulties. Shanghai Huaota Biopharmaceutical is making every effort to develop the new coronavirus neutralizing antibody cocktail, hoping to make our contribution to the continuous fight against the epidemic.

Question: What are the accomplishments that the company or yourself have achieved in 2020.

Answer: The company has achieved 3 major goals.

1) Huaota obtained clinical approvals for 4 investigational new drugs in China and the United States: In 2020, all employees of Huaota united and cooperated, regardless of the raging epidemic, and obtained in total of 9 IND approvals in China and United States. Especially our world’s first PD-L1/VEGF bispecific fusion protein project, in now initiating phase I clinical trail simultaneously in China and the United States.

2) We continue to improve the innovative drug platform: On the basis of the original hybridoma and "Trap in Mab" bispecific antibody platform, Huaota further develops and perfects technical platforms such as ADC, nanobody, single B cell, etc. The company launched a series of FIC and BIC pipelines, and continued to intensively cultivate on innovation targets.

3) The clinical team has begun to take shape: In 2020, Huaota clinical team will continue to expand, complete the phase I clinical trials of 4 projects, and continue to efficiently initiate subsequent phase II and III clinical trials.

Question: In 2021, what is your plan of development for the company or for yourself.

Answer:

1) Strengthen the advancement of clinical projects: rapidly advance the phase I clinical trial of HB0025 (PD-L1/VEGF) in China and the United States, and hope to get positive clinical research data by the end of 2021. Meanwhile, continue to promote the domestic phase I clinical trials of HOT-1030 (CD137) and HB0017 (IL-17), and continue to advance the phase II/III clinical trials of existing projects. We plan to complete 4-5 new target INDs approvals in China and the United States in 2021

2) Initiate independent financing of Shanghai Huaota Pharmaceutical Co., Ltd. to prepare for the future IPO. The primary goal in 2021 is to complete the A round of financing. In the future, Huaota will be the mainstay to promote the company quickly IPO. With the help of capital, we will bring the company's products to the market faster and better.

3) Intensify innovation, focus on the world, and focus on differentiated competition of products: actively seek foreign cooperation to build Shanghai Huaota into an innovative pharmaceutical company with unique products. The key value of Huaota is innovation. As an independent research and development company with a global focus on innovation. Our goal is to actively seek cooperative development or transfer of rights and interests in overseas markets under the premise of independently developing products in the Chinese market, and quickly promote the simultaneous development of different regional markets to maximize products value.

Question: Could you please talk about your message and expectation for the subdivision of the track in your industry?

Answer: The track of the bio-innovative drug industry is crowded, so pharmaceutical innovation needs to meet clinical needs. It is from the patient's perspective to provide patients with cheap and useful new drugs. This should also be the original intention of every drug maker. Pharmaceutical counterparts need to improve the overall capabilities of China's pharmaceutical industry through healthy competition and mergers and cooperation and avoid excessive differentiation of R&D forces and excessive pursuit of periodic returns. I hope to see more "Chinese innovations" recognized by the world in the future. Finally, Huaota will always adhere to the concept of innovation to change the world, through independent research and development and global patents, we will promote our innovative products to the world and benefit mankind.

Dr. Zhu Xiangyang

General Manager of Huabo Biopharm Co., Ltd., and Shanghai Huaota Biopharmaceutical Co., Ltd.

Dr. Zhu Xiangyang, ‘Leading Talents in Zhejiang Province’, is an expert in biopharmaceutical research and development and process development. He has extensive experience in monoclonal antibody screening and identification, engineering modification of dual target antibodies, cell line establishment, process development, technology transfer, and pilot plant design and construction. Dr. Zhu is the general manager of Shanghai Huaota Biopharmaceutical Co., Ltd., and is responsible for the company’s global biopharmaceutical research and development, leading the team to complete 6 projects for IND application in both China and the United States (currently 2 phase III trials, 3 phase II trials, and 2 phase I trials). At the same time, there are more than 10 early research and development projects, including bifunctional antibodies and ADC projects. Dr. Zhu Xiangyang has worked in different fields and locations of Boehringer Ingelheim (BI) for a long time (USA, Germany, China), led and participated more than 20 research on multiple monoclonal antibodies or dual target antibody projects. Dr. Zhu is the early project leader and inventor of Risankizumab. Risankizumab has been listed in the United States and Japan. Zhu Xiangyang received his Ph.D. in immunology from the University of Illinois.

Shanghai Huaota Biopharmaceutical Co., Ltd

Shanghai Huaota Biopharmaceutical Co., Ltd (aka ‘Huaota’) is established in September 2013, it is a subsidiary of Zhejiang Huahai Pharmaceuticals Co., Ltd. The company is committed to provide high-level and high-quality biopharmaceuticals for the global market to meet the needs of patients for the accessibility and affordability of high-end biopharmaceuticals.

Based on innovation and development, the company adopts the world's leading biopharmaceutical production technology and manufacturing equipment, and strives to build a production line that meets the GMP standards of CFDA, US FDA, EU EMA. There are 200L and 1000L disposable bioreactors, and advanced waterless filling production lines including prefilled needle filling.

The company has established a biological drug development and production team with international advanced level, led by Dr. Zhu Xiangyang.

We are a growing biotechnology research and development company dedicated to designing, optimizing and continuously innovating tumor therapies to improve the living standards of patients. We will use genetic engineering technology and dual-target platform technology with independent intellectual property rights to develop multifunctional antibodies and recombinant protein drugs against tumors and autoimmune diseases. We strive to create a benign competitive environment of joy, mutual influence and mutual supervision. Let every employee understand what they are doing and work hard to create new drugs that can change the world.

2021 Enmorehealthcare Biological Industry Conference

Dr. Zhu Xiangyang will participate in the 6th Enmorehealthcare Biological Industry Conference. On the afternoon of March 13th, the project roadshow will deliver a keynote speech on "Shanghai Huaota Bio-innovative Drug Research and Development Progress and Layout". stay tuned!